ESSA Pharma Inc. (NASDAQ:EPIX) Declares $1.69 -- Dividend

Key Points

• ESSA Pharma Inc. declared a dividend of $1.69 per share on August 18th, with a payable date of August 22nd for stockholders of record as of August 19th.
• As of midday trading on Monday, the stock price for NASDAQ:EPIX was $1.91, with a market cap of $90.36 million.
• ESSA Pharma reported earnings of ($0.09) per share for the recent quarter, exceeding analysts' estimates and projecting an EPS of -0.42 for the current fiscal year.

ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI announced a -- dividend on Monday, August 18th, Wall Street Journal reports. Stockholders of record on Tuesday, August 19th will be given a dividend of 1.69 per share on Friday, August 22nd. The ex-dividend date of this dividend is Monday, August 25th.

ESSA Pharma Stock Performance

Shares of NASDAQ EPIX traded down $0.02 during midday trading on Monday, hitting $1.91. 569,637 shares of the stock traded hands, compared to its average volume of 224,138. The company has a market cap of $90.36 million, a PE ratio of -3.41 and a beta of 1.55. ESSA Pharma has a one year low of $1.40 and a one year high of $7.88. The business has a 50 day moving average price of $1.80 and a two-hundred day moving average price of $1.71.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.08. As a group, equities research analysts forecast that ESSA Pharma will post -0.42 EPS for the current fiscal year.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.